MX338490B - Metodo y composicion para tratar degeneracion macular. - Google Patents

Metodo y composicion para tratar degeneracion macular.

Info

Publication number
MX338490B
MX338490B MX2011010899A MX2011010899A MX338490B MX 338490 B MX338490 B MX 338490B MX 2011010899 A MX2011010899 A MX 2011010899A MX 2011010899 A MX2011010899 A MX 2011010899A MX 338490 B MX338490 B MX 338490B
Authority
MX
Mexico
Prior art keywords
composition
macular degeneration
treating macular
keto
prostaglandin
Prior art date
Application number
MX2011010899A
Other languages
English (en)
Other versions
MX2011010899A (es
Inventor
John Cuppoletti
Ryuji Euno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MX2011010899A publication Critical patent/MX2011010899A/es
Publication of MX338490B publication Critical patent/MX338490B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una composición para tratar degeneración macular en un sujeto mamífero, que comprende una cantidad efectiva de un compuesto de 15-ceto-prostaglandina, tal como éster isopropílico de 13,14- dihidro-1 5-ceto-20-etil-prostaglandina F20.
MX2011010899A 2009-04-15 2010-04-15 Metodo y composicion para tratar degeneracion macular. MX338490B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16951209P 2009-04-15 2009-04-15
US12/758,550 US8609729B2 (en) 2009-04-15 2010-04-12 Method for treating macular degeneration
PCT/JP2010/057108 WO2010119986A1 (en) 2009-04-15 2010-04-15 Method and composition for treating macular degeneration

Publications (2)

Publication Number Publication Date
MX2011010899A MX2011010899A (es) 2011-11-01
MX338490B true MX338490B (es) 2016-04-18

Family

ID=42981459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010899A MX338490B (es) 2009-04-15 2010-04-15 Metodo y composicion para tratar degeneracion macular.

Country Status (16)

Country Link
US (2) US8609729B2 (es)
EP (1) EP2419107A1 (es)
JP (2) JP6109476B2 (es)
KR (1) KR20120018158A (es)
CN (1) CN102458413B (es)
AR (1) AR076298A1 (es)
AU (1) AU2010237744B2 (es)
BR (1) BRPI1016081A2 (es)
CA (1) CA2757762A1 (es)
IL (1) IL215556A0 (es)
MX (1) MX338490B (es)
NZ (1) NZ596035A (es)
RU (1) RU2548762C2 (es)
TW (1) TWI501769B (es)
WO (1) WO2010119986A1 (es)
ZA (1) ZA201108151B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
TW201545748A (zh) * 2014-02-21 2015-12-16 Univ Kagawa Nat Univ Corp 伴隨老年性黃斑部病變的地圖狀萎縮的處置用的醫藥組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
EP0308135B1 (en) * 1987-09-18 1992-11-19 R-Tech Ueno Ltd. Ocular hypotensive agents
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
EP0503887B1 (en) 1991-03-14 1996-08-28 R-Tech Ueno Ltd. Promotion of wound-healing with 15-keto-prostaglandin compounds
JP2592196B2 (ja) * 1991-10-02 1997-03-19 株式会社アールテック・ウエノ 脈絡膜血流量増加剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
EP0857718B1 (en) 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
AU3588797A (en) 1996-07-03 1998-01-21 Board Of Regents Of The University Of Oklahoma, The Enhancement of skin pigmentation by prostaglandins
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
PL371128A1 (en) * 2001-12-12 2005-06-13 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
US7381404B2 (en) * 2002-07-02 2008-06-03 The Regents Of The University Of California Treatment for dry macular degeneration
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
WO2013074840A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration

Also Published As

Publication number Publication date
WO2010119986A1 (en) 2010-10-21
NZ596035A (en) 2013-06-28
JP2015205915A (ja) 2015-11-19
US20140066506A1 (en) 2014-03-06
JP6109476B2 (ja) 2017-04-05
CN102458413A (zh) 2012-05-16
EP2419107A1 (en) 2012-02-22
BRPI1016081A2 (pt) 2017-07-18
US20100267832A1 (en) 2010-10-21
ZA201108151B (en) 2012-07-25
MX2011010899A (es) 2011-11-01
RU2548762C2 (ru) 2015-04-20
TWI501769B (zh) 2015-10-01
AU2010237744A1 (en) 2011-11-17
RU2011146128A (ru) 2013-05-20
CN102458413B (zh) 2015-05-20
US8609729B2 (en) 2013-12-17
AU2010237744B2 (en) 2015-11-26
CA2757762A1 (en) 2010-10-21
AR076298A1 (es) 2011-06-01
JP2012524025A (ja) 2012-10-11
IL215556A0 (en) 2011-12-29
KR20120018158A (ko) 2012-02-29
TW201039830A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
NZ596228A (en) Compositions and methods for the treatment of inflammation
MX2012007981A (es) Derivados de fumarato de acido graso y sus usos.
BRPI1014472A8 (pt) Método para produzir um derivado de ácido graxo, microrganismo engenheirado geneticamente, derivado de ácido graxo e composição de biocombustível
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
IN2012DN03883A (es)
MY185898A (en) Methods for increasing tolerance to abiotic stress in plants
SG10201808661XA (en) Method of treating obesity using antioxidant inflammation modulators
TW200714283A (en) Method and composition for treating peripheral vascular diseases
NZ725224A (en) Compositions comprising a biological control agent and an insecticide
PH12013502284A1 (en) Protein-active agent conjugates and method for preparing the same
GB2481952A (en) Plant growth regulator additive
MX2013012165A (es) Composicion y metodo para mejorar una respuesta inmune.
WO2009134380A3 (en) Super fast-acting insulin compositions
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MX2011012181A (es) Composicion y metodo para controlar enfermedades de plantas.
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
MY159244A (en) Method of reducing intraocular pressure in humans
MX339198B (es) Composicion y metodo para tratar condiciones de la piel.
WO2010132175A3 (en) Composition incorporating emollient oils into bodywash
WO2011135544A3 (en) Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy
MX336787B (es) Microorganismos deseñados geneticamente que comprenden 4-hidroxibenzoil-coa tioesterasas y metodos de uso de los mismos para producir acidos grasos libes y derivados de acidos grasos.
MX338490B (es) Metodo y composicion para tratar degeneracion macular.
WO2010127197A3 (en) Method and composition for treating diabetic ketoacidosis
WO2012061086A3 (en) Method of treating neuroendocrine tumors

Legal Events

Date Code Title Description
FG Grant or registration